Risk Factors for Fluconazole-Resistant Candida glabrata Bloodstream Infections
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bloodstream infections (BSIs) caused by Candida glabrata have increased substantially. Candida glabrata is often associated with resistance to fluconazole therapy. However, to our knowledge, risk factors for fluconazole-resistant C glabrata BSIs have not been studied. METHODS: A case-case-control study was conducted at 3 hospitals from January 1, 2003, to May 31, 2007. The 2 case groups included patients with fluconazole-resistant C glabrata BSIs (minimum inhibitory concentration > or =16 microg/mL) and patients with fluconazole-susceptible C glabrata BSIs (minimum inhibitory concentration < or =8 microg/mL). Hospitalized patients without C glabrata BSIs were randomly selected for inclusion in the control group and were frequency matched to cases on the basis of time at risk. Two case-control studies were performed using this shared control group. The primary risk factor of interest, previous fluconazole use, was evaluated at multivariate analyses, adjusting for demographic data, comorbid conditions, and antimicrobial exposures. RESULTS: We included 76 patients with fluconazole-resistant C glabrata BSIs, 68 patients with fluconazole-susceptible C glabrata BSIs, and 512 control patients. Previous fluconazole use (adjusted odds ratio [95% confidence interval], 2.3 [1.3-4.2]) and linezolid use (4.6 [2.2-9.3]) were independent risk factors for fluconazole-resistant C glabrata BSIs; previous cefepime use (2.2 [1.2-3.9]) and metronidazole use (2.0 [1.1-3.5]) were independent risk factors for fluconazole-susceptible C glabrata BSIs. CONCLUSIONS: Previous fluconazole use is a significant risk factor for health care-associated fluconazole-resistant C glabrata BSIs. Future studies will be needed to evaluate the effect of decreasing fluconazole use on rates of fluconazole-resistant C glabrata BSIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478 · cited 2×
“02 Time at risk, median (interquartile range), d 23 (12-44) 17 (9-27) .”
Rangel‐Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, Jr., Jarvis, W., Dawson, J., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/520194 · Cited by 430
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of the following criteria: (1) receipt within the previous 30 days”
Pfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269 · cited 1×
“02 Time at risk, median (interquartile range), d 23 (12-44) 17 (9-27) .”
Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01130-5 · Cited by 209
Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., & Gottfredsson, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3489-3492.2002 · Cited by 188
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“C. glabrata is also able to develop high-level resistance after exposure to azole antifungals (Fidel et al., 1999; Lee et al., 2009) and is one of the most frequent species isolated in breakthrough infections from patients receiving azole prophylaxis (Bennett et al., 2004; Imhof et al., 2004;…”
BackgroundAntifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
The Candida Pathogenic Species Complex
Turner, S. A., & Butler, G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019778 · Cited by 336
Metadata
- Authors
- Lee, I., Fishman, N. O., Zaoutis, T. E., Morales, K. H., Weiner, M. G., Synnestvedt, M., Nachamkin, I., & Lautenbach, E.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-02-23
- Volume
- 169
- Issue
- 4
- Pages
- 379
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2005467096
- Cited by
- 81
- References
- 13
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.